Immune Pharmaceuticals Files for Chapter 11 Protection
February 19, 2019 07:38 ET
|
Immune Pharmaceuticals, Inc.
FORT LEE, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the...
Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction
December 18, 2018 08:30 ET
|
Immune Pharmaceuticals, Inc.
FORT LEE, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or “the Company”), a biopharmaceutical company developing novel therapeutic agents for the...
UPDATE -- Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders
December 06, 2018 09:41 ET
|
Immune Pharmaceuticals, Inc.
Meeting adjourned in order to gather additional votes FORT LEE, N.J., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB; IMNP) (“Immune” or the “Company”) a biopharmaceutical...
Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders
December 06, 2018 09:00 ET
|
Immune Pharmaceuticals, Inc.
FORT LEE, N.J., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the...
Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights
November 27, 2018 07:30 ET
|
Immune Pharmaceuticals, Inc.
Immune Receives $500,000 for Option; If Exercised, Total Deal Value Could Exceed $17.5 Million FORT LEE, N.J. and NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB:...
Immune Pharmaceuticals Reschedules Corporate Update Call
November 19, 2018 17:53 ET
|
Immune Pharmaceuticals, Inc.
Conference call with live audio webcast rescheduled until Tuesday, November 27th at 8:30 am ET FORT LEE, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune”...
Immune Pharmaceuticals Schedules Corporate Update Call
November 16, 2018 08:30 ET
|
Immune Pharmaceuticals, Inc.
Conference call with live audio webcast on Tuesday, November 20th at 8:30 am ET FORT LEE, N.J., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the...
New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid
October 29, 2018 07:30 ET
|
Immune Pharmaceuticals, Inc.
No anti-drug antibodies observed and multidose pharmacokinetics as expected FORT LEE, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”),...
Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma
October 17, 2018 09:00 ET
|
Immune Pharmaceuticals, Inc.
A broad anti-inflammatory effect observed FORT LEE, N.J., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company...
Immune Pharmaceuticals Announces $5 Million Financing
October 10, 2018 16:30 ET
|
Immune Pharmaceuticals, Inc.
Company to launch bertilimumab partnering process in the current quarter FORT LEE, N.J., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a...